Chryseriol alleviate psoriasis inflammation and keratinocyte hyperproliferation via regulating AKT/NF-kappaB signaling pathway (PRJCA042308)

We established CHR as a multifunctional anti-psoriatic agent that simultaneously addresses epidermal dysfunction (reducing keratinocyte hyperproliferation) and immune dysregulation (normalizing Th1/Th17 balance) through precise modulation of the AKT/NF-?B cascade. This mechanism indicated that CHR acted as a promising therapeutic candidate for psoriasis management.